14 results on '"Montserrat Robustillo-Villarino"'
Search Results
2. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
- Author
-
Juan José Alegre-Sancho, Victoria Núñez-Monje, Cristina Campos-Fernández, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Teresa Pedraz-Penalva, Carolina Peña-González, Isabel de la Morena, Diego Bedoya-Sanchís, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martinez-Cristóbal, Francisco Javier Navarro-Blasco, Jose Miguel Senabre-Gallego, and Francisca Sivera
- Subjects
secukinumab ,psoriatic arthritis ,real-world evidence ,effectiveness ,persistence ,Medicine (General) ,R5-920 - Abstract
IntroductionPsoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinumab, a biologic disease-modifying antirheumatic drug (bDMARD), has extensive clinical evidence of efficacy and safety in the treatment of PsA but data in clinical practice are still limited. This study aims to provide real-world evidence on secukinumab use, effectiveness, and persistence in PsA.MethodsA retrospective, multicenter study was conducted on patients diagnosed with PsA and treated with secukinumab up to June 2021 at 12 centers in the Valencian Community (Spain). Data on DAS28-CRP, DAPSA, Tender and Swollen Joint Counts (TJC, SJC), enthesitis, dactylitis, skin and nail involvement, pain, patient and physician global assessment (ptGA, phGA) using 100-mm visual analog scale (VAS), and persistence for up to 24 months were collected.ResultsA total of 178 patients were included (49% men; mean [standard deviation, SD] age: 51.4 [10.5] years; 39% obese). Secukinumab was used as a first-, second-, or ≥ third-line bDMARD in 37, 21, and 42% of patients, respectively. The percentage of patients achieving at least low disease activity (DAS28-CRP ≤ 3.2) increased from 25% at baseline to 66% at month 6 (M6) and was maintained (75%) up to M24. Mean (SD) DAS28-CRP baseline values (3.9 [1.2]) decreased to 2.9 (1.1) (p
- Published
- 2023
- Full Text
- View/download PDF
3. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
- Author
-
Francisca Sivera, Victoria Núñez-Monje, Cristina Campos-Fernández, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Juan Miguel López-Gómez, Carolina Peña-González, Isabel de la Morena, Diego Bedoya-Sanchís, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martínez-Cristóbal, Francisco Javier Navarro-Blasco, José Miguel Senabre-Gallego, and Juan José Alegre-Sancho
- Subjects
secukinumab ,effectiveness ,axial spondyloarthritis ,non-radiographic axial spondyloarthritis ,ankylosing spondylitis ,real-world evidence ,Medicine (General) ,R5-920 - Abstract
BackgroundSecukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA.Patients and methodsRetrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and ≥ third) for up to 24 months.Results221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a ≥ hird-line in 28%. The percentage of patients achieving low disease activity (BASDAI
- Published
- 2023
- Full Text
- View/download PDF
4. Estudio descriptivo de una cohorte de pacientes con COVID-19 hospitalizados en España
- Author
-
Laura Álvarez-Arroyo, Francisco J. Carrera-Hueso, David El-Qutob, Montserrat Robustillo-Villarino, Ana M. Girona-Sanz, María T. Pin-Godos, Paula Sánchez-Monzó, Rafael Martínez-Gonzálbez, Sonia Cepeda-Madrigal, and Fernando Martínez-Martínez
- Subjects
Public aspects of medicine ,RA1-1270 ,Internal medicine ,RC31-1245 - Published
- 2021
- Full Text
- View/download PDF
5. Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients.
- Author
-
Raquel López-Mejías, Fernanda Genre, Sara Remuzgo-Martínez, Montserrat Robustillo-Villarino, Mercedes García-Bermúdez, Javier Llorca, Alfonso Corrales, Carlos González-Juanatey, Begoña Ubilla, José A Miranda-Filloy, Verónica Mijares, Trinitario Pina, Ricardo Blanco, Juan J Alegre-Sancho, Marco A Ramírez Huaranga, María D Mínguez Sánchez, Beatriz Tejera Segura, Iván Ferraz-Amaro, Esther Vicente, F David Carmona, Santos Castañeda, Javier Martín, and Miguel A González-Gay
- Subjects
Medicine ,Science - Abstract
To determine whether the interleukin-33 (IL-33)-interleukin-1 receptor like 1 (IL-1RL1) signaling pathway is implicated in the risk of subclinical atherosclerosis in patients with rheumatoid arthritis (RA).A total of 576 Spanish RA patients from Northern Spain were genotyped for 6 well-known IL33-IL1RL1 polymorphisms (IL33 rs3939286, IL33 rs7025417, IL33 rs7044343, IL1RL1 rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714) by TaqMan genotyping assay. The presence of subclinical atherosclerosis was determined by the assessment of carotid intima-media thickness (cIMT) by carotid ultrasound (US).RA patients carrying the TT genotype of the IL33 rs3939286 polymorphism had lower cIMT values than those homozygous for the CC genotype (mean ± standard deviation (SD): 0.71 ± 0.14 mm versus 0.76 ± 0.16 mm, respectively) while patients carrying the CT genotype had intermediate cIMT values (mean ± SD: 0.73 ± 0.17 mm). Moreover, RA patients carrying the mutant allele T of the IL33 rs3939286 polymorphism exhibited significantly lower cIMT values than those carrying the wild allele C (mean ± SD: 0.72 ± 0.16 mm versus 0.75 ± 0.18 mm respectively; p = 0.04). The association of both genotype and allele frequencies of IL33 rs3939286 and cIMT levels remained statistically significant after adjustment for sex, age at the time of US study, follow-up and center (p = 0.006 and p = 0.0023, respectively), evidencing that the potential effect conferred by IL33 rs3939286 may be independent of confounder factors. No association with other IL33-IL1RL1 genetic variants was observed.In conclusion, our results may suggest a potential protective effect of the IL33 rs3939286 allele T in the risk of subclinical atherosclerosis in patients with RA.
- Published
- 2015
- Full Text
- View/download PDF
6. Evaluación de la esfera sexual en pacientes con artritis psoriásica
- Author
-
Montserrat Robustillo-Villarino, Juan José Alegre-Sancho, and María de los Ángeles Martínez-Ferrer
- Subjects
Rheumatology - Published
- 2023
- Full Text
- View/download PDF
7. Evaluation of the sexual sphere in patients with psoriatic arthritis
- Author
-
Montserrat Robustillo-Villarino, Juan José Alegre-Sancho, and María de los Ángeles Martínez-Ferrer
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
8. Descriptive study of a cohort of COVID-19 hospitalized patients in Spain
- Author
-
Paula Sánchez-Monzó, Ana M. Girona-Sanz, Rafael Martínez-Gonzálbez, Sonia Cepeda-Madrigal, Fernando Martínez-Martínez, David El-Qutob, Montserrat Robustillo-Villarino, María T. Pin-Godos, Francisco J. Carrera-Hueso, and Laura Álvarez-Arroyo
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,law.invention ,Malaise ,Cohort Studies ,law ,Diabetes mellitus ,medicine ,Humans ,Internal medicine ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,COVID-19 ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,RC31-1245 ,Intensive care unit ,Hospitalization ,Blood pressure ,Spain ,Cohort ,COVID-19. SARS-CoV-2. Viral pneumonia. Cohort study. Coronavirus ,Female ,Public aspects of medicine ,RA1-1270 ,medicine.symptom ,business ,Dyslipidemia ,Cohort study - Abstract
Several descriptive cohort studies of patients affected by COVID-19 have been published.To describe the characteristics of patients with SARS-CoV-2 infection who were admitted to Hospital Universitario la Plana, Castellón, Spain.Retrospective, observational cohort study that included 18-year-old or older patients who were consecutively admitted with SARS-CoV2 confirmed infection. Demographic characteristics, comorbidities, clinical symptoms, laboratory results and radiological tests are described.The study included 255 patients with a mean age of 70 years; 54.9 % were males. Most common comorbidities were high blood pressure (58 %), dyslipidemia (42.4 %), diabetes (25.5 %) and obesity (24.3 %). Median number of days from the onset of clinical symptoms prior to hospital admission was seven. Most common manifestations prior to admission were fever (74.5 %), dry cough (61.2 %), malaise (51.8 %) and dyspnea (51.0 %); 19 patients (7.4 %) were admitted to the intensive care unit, where mortality was 50 %; overall mortality was 16.9 %.Our cohort reflects similar characteristics to those of other European series. Mortality was lower than that in similar studies.Se han publicado varios estudios descriptivos de cohortes de pacientes afectados por COVID-19.Describir las características de pacientes con infección por SARS-CoV-2 que ingresaron al Hospital Universitario de La Plana, Castellón, España.Estudio observacional de cohortes retrospectivo, que incluyó pacientes de 18 años o mayores que ingresaron en forma consecutiva con infección confirmada por SARS-CoV2; se describen características demográficas, comorbilidades, síntomas clínicos, resultados de laboratorio y pruebas radiológicas.El estudio incluyó 255 pacientes con edad promedio de 70 años; 54.9 % fue del sexo masculino. Las comorbilidades más frecuentes fueron hipertensión arterial (58 %), dislipemia (42.4 %), diabetes (25.5 %) y obesidad (24.3 %). La mediana de días del inicio de síntomas clínicos antes del ingreso fue de siete. Las manifestaciones más frecuentes previas al ingreso fueron fiebre (74.5 %), tos seca (61.2 %), malestar general (51.8 %) y disnea (51.0 %); 19 pacientes (7.4 %) ingresaron a la unidad de cuidados intensivos, donde la mortalidad fue de 50 %; la mortalidad total fue de 16.9 %.Nuestra cohorte refleja características similares a las de otras series europeas. La mortalidad fue inferior a la de estudios similares.
- Published
- 2023
- Full Text
- View/download PDF
9. Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports
- Author
-
Montserrat Robustillo Villarino, Lydia Montolio Chiva, and Ana Victoria Carro Martínez
- Subjects
rheumatoid arthritis ,Myeloid ,Inflammatory arthritis ,tumour necrosis factor inhibitors ,Inflammation ,Case Report ,RM1-950 ,Granulocyte ,medicine ,Macrophage ,pain ,leukapheresis ,disease-modifying anti-rheumatic drugs ,Pharmacology ,psoriatic arthritis ,business.industry ,Monocyte ,General Medicine ,Leukapheresis ,medicine.disease ,medicine.anatomical_structure ,Apheresis ,Immunology ,Molecular Medicine ,non-steroidal anti-inflammatory agents ,Therapeutics. Pharmacology ,medicine.symptom ,business - Abstract
Drug therapy of immune-mediated inflammatory arthropathies is not always satisfactory, and there is a risk of adverse events. Granulocyte and monocyte/macrophage apheresis (GMA) is a non-pharmacological therapeutic option that is beneficial and very well tolerated. GMA involves passing blood through a column with cellulose acetate beads to remove increased and activated myeloid lineage cells and improve the cytokine profile. The technique reduces pain and inflammation. We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis. The results were positive, and no adverse events were reported.
- Published
- 2021
10. Estudio descriptivo de una cohorte de pacientes con COVID-19 hospitalizados en España
- Author
-
Paula Sánchez-Monzó, Rafael Martínez-Gonzálbez, Sonia Cepeda-Madrigal, Fernando Martínez-Martínez, Laura Álvarez-Arroyo, María T. Pin-Godos, Ana M. Girona-Sanz, Montserrat Robustillo-Villarino, Francisco J. Carrera-Hueso, and David El-Qutob
- Subjects
General Medicine - Abstract
Antecedentes: Se han publicado varios estudios descriptivos de cohortes de pacientes afectados por COVID-19. Objetivo: Describir las caracteristicas de pacientes con infeccion por SARS-CoV-2 que ingresaron al Hospital Universitario de La Plana, Castellon, Espana. Metodos: Estudio observacional de cohortes retrospectivo, que incluyo pacientes de 18 anos o mayores que ingresaron en forma consecutiva con infeccion confirmada por SARS-CoV2; se describen caracteristicas demograficas, comorbilidades, sintomas clinicos, resultados de laboratorio y pruebas radiologicas. Resultados: El estudio incluyo 255 pacientes con edad promedio de 70 anos; 54.9 % fue del sexo masculino. Las comorbilidades mas frecuentes fueron hipertension arterial (58 %), dislipemia (42.4 %), diabetes (25.5 %) y obesidad (24.3 %). La mediana de dias del inicio de sintomas clinicos antes del ingreso fue de siete. Las manifestaciones mas frecuentes previas al ingreso fueron fiebre (74.5 %), tos seca (61.2 %), malestar general (51.8 %) y disnea (51.0 %); 19 pacientes (7.4 %) ingresaron a la unidad de cuidados intensivos, donde la mortalidad fue de 50 %; la mortalidad total fue de 16.9 %. Conclusiones: Nuestra cohorte refleja caracteristicas similares a las de otras series europeas. La mortalidad fue inferior a la de estudios similares.
- Published
- 2021
- Full Text
- View/download PDF
11. Are Prognostic Factors Useful in Rheumatoid Arthritis?
- Author
-
Jesús Rodríguez Moreno and Montserrat Robustillo Villarino
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Poor prognosis ,Joint destruction ,business.industry ,General Medicine ,Early rheumatoid arthritis ,Disease ,medicine.disease ,Functional disability ,Internal medicine ,Rheumatoid arthritis ,Physical therapy ,Etiology ,Medicine ,business - Abstract
Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology, which predominantly affects joints and that confers poor functional and vital outcome. In many patients the inflammatory process is maintained for years, and results in joint destruction and long-term functional disability. Prognostic factors (PF) are demographic, clinical, laboratory and/or radiographic and should be evaluated at the onset of the disease, providing the physician prospective information on patient outcome. The challenge for the rheumatologist is to identify patients who present a poor prognosis in early rheumatoid arthritis and formulate treatment accordingly. © 2010 Elsevier Espa ˜
- Published
- 2011
- Full Text
- View/download PDF
12. Joint involvement secondary to Epstein-Barr virus
- Author
-
Carlos Manuel, Feced Olmos, Meritxell, Fernández Matilla, Montserrat, Robustillo Villarino, Isabel, de la Morena Barrio, and Juan José, Alegre Sancho
- Subjects
Adult ,Epstein-Barr Virus Infections ,Arthritis ,Humans ,Female ,Middle Aged ,Aged - Abstract
We describe a group of patients with Epstein-Barr virus (EBV) infection and joint involvement. Between February 2011 and January 2012, there were six cases in our unit. Two presented with a pattern similar to rheumatoid arthritis, three had polyarthralgia with an inflammatory pattern and only one patient had asymmetrical oligoarthritis of large joints. They were all women aged between 25 and 75 (4 were of child-bearing potential). Diagnosis in all the cases was made by exclusion of other possible causes and negative IgM were obtained for the rest of the "Herpesviridae" family viruses. In our series, EBV joint involvement was more common in women of childbearing potential. Clinical presentation was heterogeneous but was predominantly in the form of inflammatory joint pain. When it presents in the form of symmetrical polyarthritis, it can become chronic and require the use of disease-modifying anti-rheumatic drugs.
- Published
- 2015
13. [Are useful prognostic factors in rheumatoid arthritis?]
- Author
-
Montserrat, Robustillo Villarino and Jesús, Rodríguez Moreno
- Subjects
Arthritis, Rheumatoid ,Socioeconomic Factors ,Antirheumatic Agents ,Remission Induction ,Disease Progression ,Humans ,Prognosis - Abstract
Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology, which predominantly affects joints and that confers poor functional and vital outcome. In many patients the inflammatory process is maintained for years, and results in joint destruction and long-term functional disability. Prognostic factors (PF) are demographic, clinical, laboratory and/or radiographic and should be evaluated at the onset of the disease, providing the physician prospective information on patient outcome. The challenge for the rheumatologist is to identify patients who present a poor prognosis in early rheumatoid arthritis and formulate treatment accordingly.
- Published
- 2010
14. Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports
- Author
-
Ana Victoria Carro Martínez, Lydia Montolio Chiva, and Montserrat Robustillo Villarino
- Subjects
disease-modifying anti-rheumatic drugs ,leukapheresis ,non-steroidal anti-inflammatory agents ,pain ,psoriatic arthritis ,rheumatoid arthritis ,tumour necrosis factor inhibitors ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Drug therapy of immune-mediated inflammatory arthropathies is not always satisfactory, and there is a risk of adverse events. Granulocyte and monocyte/macrophage apheresis (GMA) is a non-pharmacological therapeutic option that is beneficial and very well tolerated. GMA involves passing blood through a column with cellulose acetate beads to remove increased and activated myeloid lineage cells and improve the cytokine profile. The technique reduces pain and inflammation. We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis. The results were positive, and no adverse events were reported.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.